Business
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients
About this update from Cogent Biosciences, Inc.
[{"type":"text","content":"Bezuclastinib mean TSS reduction deepens to –32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase at 48 weeks, with 83% rate of normalizationStrong evidence of bezuclastinib’s potential as first disease modifying agent for NonAdvSM patient population given clear correlation between objective measures of disease burden and symptomatic improvement WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced additional clinical results from the pivotal SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the American Academy of Allergy Asthma & Immunology (AAAAI) Annual Meeting. As previously reported, bezuclastinib demonstrated clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints. New results highlight the deepening of clinical benefit over longer treatment duration, the benefit of bezuclastinib in populations with high unmet need, and bezuclastinib’s impact on bone mineral density as additional evidence of disease modification. “The additional SUMMIT data presented at AAAAI today reinforce our belief that bezuclastinib can rapidly and meaningfully improve a wide variety of symptoms that impact the daily lives of patients with NonAdvanced SM,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “These posters underscore the significance of our findings and build upon the data we shared at ASH last year. Addingall these results together, bezuclastinib’s profile continues to be a very active, well-tolerated option for NonAdvSM patients, which we believe has the opportunity to become the preferred standard of care.” Data Highlights from the SUMMIT Posters Treatment with bezuclastinib resulted in rapid, durable, statistically significant symptomatic improvements which continued to deepen out to 48 weeks: Patients on bezuclastinib reported a -32.0 point mean change in TSS, representing a 56% relative improvement in TSS from baseline86% of patients achieved a clinically meaningful threshold of 30% improvement in symptoms99% of patients had at least...